Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  McBride, Ali ^a   Westervelt, Peter ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Acute renal failure; Adverse events; Allopurinol; Hematologic malignancies; Management; Prophylactic therapy; Rasburicase; Solid tumors; Tumor lysis syndrome (TLS); Uric acid

Indexed keywords

ALLANTOIN; ALLOPURINOL; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BICARBONATE; CALCIUM PHOSPHATE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROCORTISONE; HYPOXANTHINE; LACTATE DEHYDROGENASE; RASBURICASE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNINDEXED DRUG; URIC ACID; VINBLASTINE; XANTHINE; XANTHINE OXIDASE; ZOLEDRONIC ACID;

ACUTE LEUKEMIA; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEST TIGHTNESS; COLON CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSPNEA; FLUID THERAPY; HEART PALPITATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOCALCEMIA; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; MELANOMA; METABOLIC DISORDER; METASTATIC MELANOMA; OLIGURIA; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; REHYDRATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOLID TUMOR; SYMPTOM; TREATMENT INDICATION; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 84870873342     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-75     Document Type: Review

References (55)

1. The tumor lysis syndrome. Howard SC, Jones DP, Pui CH, N Engl J Med 2011 364 1844 1854 10.1056/NEJMra0904569 21561350
2. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, et al. J Clin Oncol 2010 28 4207 4213 10.1200/JCO.2009.26.8896 20713865
3. Tumor lysis syndrome-a treatment guide. Wetzstein GA, Oncology 2002 5 31 4
4. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, et al. Intern Med 2010 49 991 994 10.2169/internalmedicine.49.3153 20519814
5. Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay (ATP-TCA). Qian KQ, Ye H, Xiao YW, Bao YY, Qi CJ, Int J Gen Med 2009 2 1 4 20360879
6. Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung. Shenoy C, QJM 2009 102 71 73 10.1093/qjmed/hcn129 18829711
7. Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. Noh GY, Choe DH, Kim CH, Lee JC, J Clin Oncol 2008 26 6005 6006 10.1200/JCO.2008.19.4308 19029410
8. Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer. Ajzensztejn D, Hegde VS, Lee SM, J Clin Oncol 2006 24 2389 2391 10.1200/JCO.2005.02.8753 16710040 (Pubitemid 46630674)
9. Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I, Med Oncol 2005 22 203 6 10.1385/MO:22:2:203 15965285 (Pubitemid 41003455)
10. Tumor lysis syndrome: current perspective. Hochberg J, Cairo MS, Haematologica 2008 93 9 13 10.3324/haematol.12327 18166779 (Pubitemid 351156145)
11. Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma-a case report. Ahamed SM, Varma RS, Mathew T, Hamide A, Badhe BA, Indian J Pathol Microbiol 2006 49 26 28 16625969
12. Pitfalls in predicting tumor lysis syndrome. Howard SC, Pui CH, Leuk Lymphoma 2006 47 782 785 10.1080/10428190600765798 16753859 (Pubitemid 43840630)
13. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS, J Clin Oncol 2008 26 2767 2778 10.1200/JCO.2007.15.0177 18509186
14. Tumour lysis syndrome: new therapeutic strategies and classification. Cairo MS, Bishop M, Br J Haematol 2004 127 3 11 10.1111/j.1365-2141.2004.05094.x 15384972 (Pubitemid 39331101)
15. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Hande KR, Garrow GC, Am J Med 1993 94 133 139 10.1016/0002-9343(93) 90174-N 8430709 (Pubitemid 23046437)
16. Tumor lysis syndrome in solid tumors. Mott FE, Esana A, Chakmakjian C, Herrington JD, Support Cancer Ther 2005 2 188 191 10.3816/SCT.2005.n.012 18628171
17. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. Krishnan G, D'Silva K, Al-Janadi A, J Clin Oncol 2008 26 2406 2408 10.1200/JCO.2007.14.7603 18467734
18. Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. Godoy H, Kesterson JP, Lele S, Int J Gynaecol Obstet 2010 109 254 10.1016/j.ijgo.2010.02.005 20362289
19. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Habib GS, Saliba WR, Am J Med Sci 2002 323 155 157 10.1097/00000441-200203000-00007 11908861
20. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW, Cancer 1999 85 1055 1059 10.1002/(SICI)1097-0142(19990301)85:5<1055::AID-CNCR7>3.0.CO;2-3 10091788 (Pubitemid 29115583)
21. Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Stoves J, Richardson D, Patel H, Nephrol Dial Transplant 2001 16 188 189 10.1093/ndt/16.1.188 11209026 (Pubitemid 32051506)
22. Tumor lysis syndrome developing intraoperatively. Verma A, Mathur R, Chauhan M, Ranjan P, J Anaesthesiol Clin Pharmacol 2011 27 561 563 10.4103/0970-9185.86611 22096300
23. Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. Opyrchal M, Figanbaum T, Ghosh A, Rajkumar V, Caples S, Case Report Med 2010 2010 610969 1-3 20300188
24. Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Riccio B, Mato A, Olson EM, Berns JS, Luger S, Cancer Biol Ther 2006 5 1614 1617 10.4161/cbt.5.12.3610 17204864
25. Spontaneous tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Barquero Romero J, Catalina Fernández I, Hernández Sáez C, Jiménez Morales JL, García de la Llana F, An Med Interna 2005 22 387 389 16351493 (Pubitemid 41617776)
26. Spontaneous tumor lysis syndrome in acute lymphoblastic leukemia. Sharma SK, Malhotra P, Kumar M, Sharma A, Varma N, Singh S, J Assoc Physicians India 2005 53 828 830 16334634 (Pubitemid 41365571)
27. Acute spontaneous tumor lysis syndrome. Jasek AM, Day HJ, Am J Hematol 1994 47 129 131 10.1002/ajh.2830470212 8092128 (Pubitemid 24302283)
28. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CJ, South Med J 2007 100 916 917 10.1097/SMJ.0b013e318137a665 17902299 (Pubitemid 47367939)
29. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB, Support Care Cancer 2001 9 554 557 10.1007/s005200100276 11680837 (Pubitemid 32927888)
30. Spontaneous acute tumor lysis syndrome with advanced gastric cancer. Woo IS, Kim JS, Park MJ, Lee MS, Cheon RW, Chang HM, et al. J Korean Med Sci 2001 16 115 118 11289389 (Pubitemid 33741329)
31. Spontaneous recurrent tumor lysis syndrome in breast cancer. Sklarin NT, Markham M, Am J Clin Oncol 1995 18 71 73 10.1097/00000421-199502000-00015 7847263
32. Hyperuricemic acute renal failure in disseminated carcinoma. Crittenden DR, Ackerman GL, Arch Intern Med 1977 137 97 99 10.1001/archinte.1977. 03630130065016 831657 (Pubitemid 8104592)
33. Hyperuricemic acute renal failure. Kjellstrand CM, Cambell DC II, von Hartitzsch B, Buselmeier TJ, Arch Intern Med 1974 133 349 359 10.1001/archinte.1974.00320150023002 4283735
34. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel, Br J Haematol 2010 149 578 586 10.1111/j.1365-2141.2010.08143.x 20331465
35. Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies. Kennedy LD, Koontz S, Rao K, J Blood Med 2011 2 1 6 22287858
36. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Michallet AS, Tartas S, Coiffier B, Support Cancer Ther 2005 2 159 166 10.3816/SCT.2005.n.008 18628166
37. New insights into the epidemiology of gout. Doherty M, Rheumatology (Oxford) 2009 48 Suppl 2 i2 ii8 10.1093/rheumatology/kep086
38. National Library of Medicine: MedlinePlus: Uric acid-blood, http://www.nlm.nih.gov/medlineplus/ency/article/003476.htm
39. Renal tubular damage in rasburicase: risks of alkalinisation. van den Berg H, Reintsema AM, Ann Oncol 2004 15 175 176 10.1093/annonc/mdh023 14679141
40. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE, Metabolism 1972 21 771 778 10.1016/0026-0495(72) 90124-2 5047919
41. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. J Clin Oncol 2001 19 697 704 11157020 (Pubitemid 32119083)
42. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. Blood 2001 97 2998 3003 10.1182/blood.V97.10.2998 11342423
43. Elitek [package insert], sanofi-aventis U.S, LLC, Bridgewater, NJ 2011
44. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. Knoebel RW, Lo M, Crank CW, J Oncol Pharm Pract 2011 17 147 154 10.1177/1078155210364180 20332174
45. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Giraldez M, Puto K, Eur J Haematol 2010 85 177 179 20394650
46. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Vines AN, Shanholtz CB, Thompson JL, Ann Pharmacother 2010 44 1529 1537 10.1345/aph.1P296 20841516
47. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. Campara M, Shord SS, Haaf CM, J Clin Pharm Ther 2009 34 207 213 10.1111/j.1365-2710.2008.00994.x 19250141
48. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Reeves DJ, Bestul DJ, Pharmacotherapy 2008 28 685 690 10.1592/phco.28.6.685 18503395 (Pubitemid 351975371)
49. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M, Pharmacotherapy. 2006 26 242 247 10.1592/phco.26.2.242 16466328 (Pubitemid 43201871)
50. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD, Pharmacotherapy 2006 26 806 812 10.1592/phco.26.6.806 16716134 (Pubitemid 43807632)
51. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, et al. Bone Marrow Transplant 2006 37 997 1001 10.1038/sj.bmt. 1705379 16708061
52. A comparative evaluation of single fixed-dosing and weight-based dosing of rasburicase for tumor lysis syndrome. McBride A, Lathan SC, Boehmer L, Augustin KA, Butler SM, Westervelt PW, Pharmacotherapy, in press
53. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, et al. Ann Oncol 2011 Epub ahead of print
54. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al. Leukemia 2005 19 34 38 15510203 (Pubitemid 40090073)
55. Treatment of impending tumor lysis with single-dose rasburicase. Lee AC, Li CH, So KT, Chan R, Ann Pharmacother 2003 37 1614 1617 10.1345/aph.1D111 14565793 (Pubitemid 37315101)